Article
A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.
Pharmacogenomics - 1 May 2018
de Denus Simon, Dubé Marie-Pierre, Fouodjio René, Huynh Thao, LeBlanc Marie-Hélène, Lepage Serge, Sheppard Richard, Giannetti Nadia, Lavoie Joël, Mansour Asmaa, Provost Sylvie, Normand Valérie, Mongrain Ian, Langlois Mathieu, O'Meara Eileen, Ducharme Anique, Racine Normand, Guertin Marie-Claude, Turgeon Jacques, Phillips Michael S, Rouleau Jean-Lucien, Tardif Jean-Claude, White Michel
Abstract excerpt
AIM: To evaluate the impact of AGTR1 A1166C (rs5186) on the response to candesartan in patients with heart failure. MATERIALS & METHODS: Prospective, multicentre, open-label study. We studied 299 symptomatic patients with heart failure presenting a left ventricular ejection fraction ≤40%. RESULTS: Reductions in the primary end points of natriuretic peptides were not significantly associated with AGTR1 A1166C....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
